TrialNature medicine2022

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.

Kevin A Strauss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.